Cannon Global Investment Management LLC Buys New Position in TScan Therapeutics, Inc. (NASDAQ:TCRX)

Cannon Global Investment Management LLC bought a new stake in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 17,500 shares of the company’s stock, valued at approximately $139,000.

Separately, Pale Fire Capital SE boosted its stake in TScan Therapeutics by 30.2% during the 4th quarter. Pale Fire Capital SE now owns 21,573 shares of the company’s stock valued at $126,000 after purchasing an additional 4,998 shares during the period. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Price Performance

Shares of TScan Therapeutics stock traded down $0.39 during midday trading on Friday, hitting $5.85. 6,045,997 shares of the company were exchanged, compared to its average volume of 277,667. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.23 and a quick ratio of 5.23. The firm has a market cap of $309.23 million, a P/E ratio of -4.57 and a beta of 0.93. TScan Therapeutics, Inc. has a 52 week low of $1.93 and a 52 week high of $9.69. The firm has a 50 day simple moving average of $8.04 and a 200-day simple moving average of $6.93.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Monday, May 13th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.07). The company had revenue of $0.57 million for the quarter, compared to the consensus estimate of $3.75 million. TScan Therapeutics had a negative return on equity of 61.13% and a negative net margin of 653.50%. Research analysts forecast that TScan Therapeutics, Inc. will post -1.25 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have commented on TCRX shares. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, June 4th. Wedbush reiterated an “outperform” rating and issued a $10.00 price objective on shares of TScan Therapeutics in a research report on Monday, May 13th. BTIG Research started coverage on TScan Therapeutics in a research report on Thursday, May 16th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of TScan Therapeutics in a research report on Monday, May 13th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $12.00.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.